Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application.

[1]  P. Serruys,et al.  ANGIOGRAPHIC MAXIMAL LUMINAL DIAMETER AND APPROPRIATE DEPLOYMENT OF THE EVEROLIMUS-ELUTING BIORESORBABLE VASCULAR SCAFFOLD AS ASSESSED BY OPTICAL COHERENCE TOMOGRAPHY , 2011 .

[2]  R. Whitbourn,et al.  Clinical ResearchInterventional CardiologyEvaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes , 2011 .

[3]  Bernard Chevalier,et al.  Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes , 2010, Circulation.

[4]  P. Serruys,et al.  Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  G. Guagliumi,et al.  Angiographic, IVUS and OCT evaluation of the long-term impact of coronary disease severity at the site of overlapping drug-eluting and bare metal stents: a substudy of the ODESSA trial , 2010, Heart.

[6]  Joanna J Wykrzykowska,et al.  3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification. , 2010, JACC. Cardiovascular interventions.

[7]  Giuseppe Biondi-Zoccai,et al.  Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. , 2010, JACC. Cardiovascular interventions.

[8]  Yoshinobu Onuma,et al.  In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: An OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial , 2010 .

[9]  C. von Birgelen,et al.  Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[10]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.

[11]  David Rotger,et al.  Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. , 2008, Journal of the American College of Cardiology.

[12]  Theodore A Bass,et al.  Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). , 2008, The American journal of cardiology.

[13]  G. Stone,et al.  Chronic arterial responses to overlapping paclitaxel-eluting stents: insights from serial intravascular ultrasound analyses in the TAXUS-V and -VI trials. , 2008, JACC. Cardiovascular interventions.

[14]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.

[15]  Ju Han Kim,et al.  Inflammation and delayed endothelization with overlapping drug-eluting stents in a porcine model of in-stent restenosis. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[16]  Bernard Chevalier,et al.  Comparison of in vivo acute stent recoil between the bioabsorbable everolimus‐eluting coronary stent and the everolimus‐eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[17]  J. Ormiston,et al.  Absorbable coronary stents , 2007, The Lancet.

[18]  K. Robinson,et al.  Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents. , 2007, The Journal of invasive cardiology.

[19]  Ron Waksman,et al.  Biodegradable stents: they do their job and disappear. , 2006, The Journal of invasive cardiology.

[20]  R. Virmani,et al.  Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents , 2005, Circulation.

[21]  R. Costa,et al.  Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry. , 2010, JACC. Cardiovascular interventions.